Compare LMAT & ELVN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LMAT | ELVN |
|---|---|---|
| Founded | 1983 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.6B | 2.6B |
| IPO Year | 2006 | 2020 |
| Metric | LMAT | ELVN |
|---|---|---|
| Price | $100.82 | $39.86 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 5 | 5 |
| Target Price | ★ $105.80 | $43.40 |
| AVG Volume (30 Days) | 210.9K | ★ 552.6K |
| Earning Date | 05-05-2026 | 05-11-2026 |
| Dividend Yield | ★ 0.93% | N/A |
| EPS Growth | ★ 30.57 | 3.17 |
| EPS | ★ 0.68 | N/A |
| Revenue | ★ $249,602,000.00 | N/A |
| Revenue This Year | $14.21 | N/A |
| Revenue Next Year | $8.88 | N/A |
| P/E Ratio | $148.23 | ★ N/A |
| Revenue Growth | ★ 13.53 | N/A |
| 52 Week Low | $78.35 | $14.79 |
| 52 Week High | $118.01 | $48.53 |
| Indicator | LMAT | ELVN |
|---|---|---|
| Relative Strength Index (RSI) | 39.65 | 45.18 |
| Support Level | $82.65 | $16.84 |
| Resistance Level | $114.98 | $40.62 |
| Average True Range (ATR) | 5.12 | 2.46 |
| MACD | -1.08 | -0.50 |
| Stochastic Oscillator | 26.42 | 19.51 |
LeMaitre Vascular Inc is a provider of medical devices and human tissue cryopreservation services mainly used in the treatment of peripheral vascular disease, end-stage renal disease, and cardiovascular disease. The company develops, manufactures, and markets vascular devices to address the needs of vascular surgeons and, to a lesser extent, other specialties such as cardiac surgeons, general surgeons, and neurosurgeons. Its diversified portfolio consists of branded products used in arteries and veins that are well known to vascular surgeons. It operates across the Americas, Europe, the Middle East and Africa, and Asia Pacific, with the majority of its revenue generated from the Americas.
Enliven Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics. The product candidates of the company include ELVN-001 is designed to specifically target the BCR-ABL fusion gene product, the oncogenic driver for patients with chronic myeloid leukemia (CML), ELVN-002 is designed to inhibit wild-type HER2 and key mutations of HER2.